Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Polycystic Ovary Syndrome 1Neoplasm Metastasis 1Lung Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1

Interventions

enzalutamide 10Prednisone 6Docetaxel 5Abiraterone Acetate 4darolutamide 3olaparib 2niraparib 2abiraterone 2Pluvicto 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1radium Ra 223 dichloride 1quemliclustat 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1Ipilimumab 1Gonadotropin-Releasing Hormone 1Dexamethasone 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × Pioglitazone × 1 year × Clear all
NCT02592317 2026-06-05

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.

Phase 1 Active not recruiting
23 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡